The Efficacy of Liposomal Bupivacaine in Thoracic Surgery: A Systematic Review and Meta-Analysis.

IF 2.5 3区医学 Q2 CLINICAL NEUROLOGY

Journal of Pain Research Pub Date : 2024-11-28 eCollection Date: 2024-01-01 DOI:10.2147/JPR.S492117

Ruisong Gong, Gang Tan, Yuguang Huang

{"title":"The Efficacy of Liposomal Bupivacaine in Thoracic Surgery: A Systematic Review and Meta-Analysis.","authors":"Ruisong Gong, Gang Tan, Yuguang Huang","doi":"10.2147/JPR.S492117","DOIUrl":null,"url":null,"abstract":"Purpose: Patients undergoing thoracic surgery suffer from severe postoperative pain, and a series of complications will occur if there is no effective analgesic treatment. Liposomal bupivacaine (LB) is a novel multivesicular formulation with up to 72 hours of analgesia, which can be used in thoracic surgery. This meta-analysis aimed to evaluate the efficacy of LB in improving recovery in patients undergoing thoracic surgery compared with non-liposomal local anesthetics.Patients and methods: A literature search was conducted using PubMed, Cochrane Library, Embase, and Web of science, and to identify all observational or retrospective studies and randomized controlled trials (RCTs) from inception to December 2023. The primary outcome was the in-hospital postsurgical opioid consumption in morphine milligram equivalents (MMEs). Secondary outcomes included 24-hour postoperative MMEs, postoperative pain score in the first 24 and 48 hours, hospital length of stay (LOS), time to first ambulation, readmission, and perioperative complications. RevMan 5.3 was used for the data analysis.Results: A total of 10 studies were included in the analysis, of which eight were observational or retrospective analyses and two were RCTs. There were no significant differences in the postoperative MMEs, pain score, LOS, time to first ambulation, readmission, and perioperative complications.Conclusion: According to this meta-analysis, LB was found to be not superior to non-liposomal local anesthetics for analgesic and functional outcomes in thoracic surgery.","PeriodicalId":16661,"journal":{"name":"Journal of Pain Research","volume":"17 ","pages":"4039-4051"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611704/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JPR.S492117","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Patients undergoing thoracic surgery suffer from severe postoperative pain, and a series of complications will occur if there is no effective analgesic treatment. Liposomal bupivacaine (LB) is a novel multivesicular formulation with up to 72 hours of analgesia, which can be used in thoracic surgery. This meta-analysis aimed to evaluate the efficacy of LB in improving recovery in patients undergoing thoracic surgery compared with non-liposomal local anesthetics.

Patients and methods: A literature search was conducted using PubMed, Cochrane Library, Embase, and Web of science, and to identify all observational or retrospective studies and randomized controlled trials (RCTs) from inception to December 2023. The primary outcome was the in-hospital postsurgical opioid consumption in morphine milligram equivalents (MMEs). Secondary outcomes included 24-hour postoperative MMEs, postoperative pain score in the first 24 and 48 hours, hospital length of stay (LOS), time to first ambulation, readmission, and perioperative complications. RevMan 5.3 was used for the data analysis.

Results: A total of 10 studies were included in the analysis, of which eight were observational or retrospective analyses and two were RCTs. There were no significant differences in the postoperative MMEs, pain score, LOS, time to first ambulation, readmission, and perioperative complications.

Conclusion: According to this meta-analysis, LB was found to be not superior to non-liposomal local anesthetics for analgesic and functional outcomes in thoracic surgery.

查看原文本刊更多论文

布比卡因脂质体在胸外科手术中的疗效：系统回顾和荟萃分析。

目的：胸外科手术患者术后疼痛严重，如果不进行有效的镇痛治疗，会出现一系列并发症。布比卡因脂质体（LB）是一种新型多泡制剂，具有长达72小时的镇痛作用，可用于胸外科手术。本荟萃分析旨在评估与非脂质体局麻药相比，LB在改善胸外科手术患者康复方面的疗效。患者和方法：使用PubMed、Cochrane图书馆、Embase和Web of science进行文献检索，并确定从开始到2023年12月的所有观察性或回顾性研究和随机对照试验（rct）。主要结局是术后住院阿片类药物的吗啡毫克当量（MMEs）消耗。次要结局包括术后24小时MMEs、术后24小时和48小时疼痛评分、住院时间（LOS）、首次下床时间、再入院和围手术期并发症。采用RevMan 5.3软件进行数据分析。结果：共纳入10项研究，其中8项为观察性或回顾性分析，2项为随机对照试验。两组术后MMEs、疼痛评分、LOS、首次下床时间、再入院时间和围手术期并发症无显著差异。结论：根据这项荟萃分析，在胸外科手术中，LB并不优于非脂质体局麻药的镇痛和功能结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pain Research CLINICAL NEUROLOGY-

CiteScore

4.50

自引率

3.70%

发文量

411

审稿时长

16 weeks

期刊介绍： Journal of Pain Research is an international, peer-reviewed, open access journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication. Additionally, the journal now welcomes the submission of pain-policy-related editorials and commentaries, particularly in regard to ethical, regulatory, forensic, and other legal issues in pain medicine, and to the education of pain practitioners and researchers.